Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz
| Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Incorporated, , [2017] |
| Descrizione fisica | 1 online resource (566 pages) : color illustrations |
| Disciplina | 615.7/98 |
| Soggetto topico |
Antibody-toxin conjugates
Monoclonal antibodies Antineoplastic agents Tumors - Treatment |
| ISBN |
1-119-06084-2
1-119-06080-X 1-119-06072-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. |
| Record Nr. | UNINA-9910151742303321 |
| Hoboken, New Jersey : , : John Wiley & Sons, Incorporated, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz
| Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Incorporated, , [2017] |
| Descrizione fisica | 1 online resource (566 pages) : color illustrations |
| Disciplina | 615.7/98 |
| Soggetto topico |
Antibody-toxin conjugates
Monoclonal antibodies Antineoplastic agents Tumors - Treatment |
| ISBN |
1-119-06084-2
1-119-06080-X 1-119-06072-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. |
| Record Nr. | UNINA-9910821000603321 |
| Hoboken, New Jersey : , : John Wiley & Sons, Incorporated, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan
| Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (618 p.) |
| Disciplina |
571.967
616.0798 |
| Altri autori (Persone) | KeinanEhud |
| Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
| Record Nr. | UNINA-9910143966603321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan
| Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (618 p.) |
| Disciplina |
571.967
616.0798 |
| Altri autori (Persone) | KeinanEhud |
| Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
| ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
| Record Nr. | UNINA-9910829843303321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies / / edited by Ehud Keinan
| Catalytic antibodies / / edited by Ehud Keinan |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (618 p.) |
| Disciplina |
571.967
616.0798 |
| Altri autori (Persone) | KeinanEhud |
| Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
| ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
| Record Nr. | UNINA-9910876996603321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies [[electronic resource]]
| Catalytic antibodies [[electronic resource]] |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1991 |
| Descrizione fisica | 1 online resource (272 p.) |
| Disciplina |
591.2
591.293 |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Monoclonal antibodies
Enzymes |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-34772-1
9786612347726 0-470-51410-8 0-470-51411-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CATALYTIC ANTIBODIES; Contents; Introduction; A catalytic antibody uses a multistep kinetic sequence; Structural aspects of antibodies and antibody-antigen complexes; Nuclear magnetic resonance studies of antibody-antigen interactions; Modelling antibody combining sites: a review; Approaches to the design of semisynthetic metal-dependent catalytic antibodies; Construction of combinatorial antibody expression libraries in Escherichia coli; Catalytic antibodies: contributions from engineering and expression in Escherichia coli
The generation of antibody combining sites containing catalytic residuesGeneral discussion I; Screening combinatorial antibody libraries for catalytic acyl transfer reactions; Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies; Antibody catalysis of carbon-carbon bond formation; Characterization of the mechanism of action of a catalytic antibody; Catalytic antibodies: a new window on protein chemistry; Expanded transition state analogues; Tritylase antibodies; Final general discussion : How good are catalytic antibodies? Potential uses of catalytic antibodiesSummary; Index of contributors; Subject index |
| Record Nr. | UNINA-9910144297403321 |
| Chichester ; ; New York, : Wiley, 1991 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies [[electronic resource]]
| Catalytic antibodies [[electronic resource]] |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1991 |
| Descrizione fisica | 1 online resource (272 p.) |
| Disciplina |
591.2
591.293 |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Monoclonal antibodies
Enzymes |
| ISBN |
1-282-34772-1
9786612347726 0-470-51410-8 0-470-51411-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CATALYTIC ANTIBODIES; Contents; Introduction; A catalytic antibody uses a multistep kinetic sequence; Structural aspects of antibodies and antibody-antigen complexes; Nuclear magnetic resonance studies of antibody-antigen interactions; Modelling antibody combining sites: a review; Approaches to the design of semisynthetic metal-dependent catalytic antibodies; Construction of combinatorial antibody expression libraries in Escherichia coli; Catalytic antibodies: contributions from engineering and expression in Escherichia coli
The generation of antibody combining sites containing catalytic residuesGeneral discussion I; Screening combinatorial antibody libraries for catalytic acyl transfer reactions; Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies; Antibody catalysis of carbon-carbon bond formation; Characterization of the mechanism of action of a catalytic antibody; Catalytic antibodies: a new window on protein chemistry; Expanded transition state analogues; Tritylase antibodies; Final general discussion : How good are catalytic antibodies? Potential uses of catalytic antibodiesSummary; Index of contributors; Subject index |
| Record Nr. | UNINA-9910830358603321 |
| Chichester ; ; New York, : Wiley, 1991 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Catalytic antibodies
| Catalytic antibodies |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1991 |
| Descrizione fisica | 1 online resource (272 p.) |
| Disciplina | 574.2/93 |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Monoclonal antibodies
Enzymes |
| ISBN |
1-282-34772-1
9786612347726 0-470-51410-8 0-470-51411-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CATALYTIC ANTIBODIES; Contents; Introduction; A catalytic antibody uses a multistep kinetic sequence; Structural aspects of antibodies and antibody-antigen complexes; Nuclear magnetic resonance studies of antibody-antigen interactions; Modelling antibody combining sites: a review; Approaches to the design of semisynthetic metal-dependent catalytic antibodies; Construction of combinatorial antibody expression libraries in Escherichia coli; Catalytic antibodies: contributions from engineering and expression in Escherichia coli
The generation of antibody combining sites containing catalytic residuesGeneral discussion I; Screening combinatorial antibody libraries for catalytic acyl transfer reactions; Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies; Antibody catalysis of carbon-carbon bond formation; Characterization of the mechanism of action of a catalytic antibody; Catalytic antibodies: a new window on protein chemistry; Expanded transition state analogues; Tritylase antibodies; Final general discussion : How good are catalytic antibodies? Potential uses of catalytic antibodiesSummary; Index of contributors; Subject index |
| Record Nr. | UNINA-9910876913003321 |
| Chichester ; ; New York, : Wiley, 1991 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Current trends in monoclonal antibody development and manufacturing / / edited by Steven J. Shire ... [et. al.]
| Current trends in monoclonal antibody development and manufacturing / / edited by Steven J. Shire ... [et. al.] |
| Edizione | [2010] |
| Pubbl/distr/stampa | New York, : Springer, 2010 |
| Descrizione fisica | 1 online resource (341 p.) |
| Disciplina | 615.37 |
| Altri autori (Persone) | ShireSteven J |
| Collana | Biotechnology: pharmaceutical aspects |
| Soggetto topico |
Monoclonal antibodies
Immunology |
| ISBN |
0-387-76643-X
1-282-83076-7 1-4614-2491-7 9786612830761 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910708105503321 |
| New York, : Springer, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Human antibodies
| Human antibodies |
| Pubbl/distr/stampa | Netherlands, : IOS Press |
| Disciplina | 616.0798 |
| Soggetto topico |
Hybridomas
Monoclonal antibodies |
| Soggetto genere / forma | Periodicals. |
| ISSN | 1875-869X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910154529203321 |
| Netherlands, : IOS Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
